48 results on '"Sachdeva, Kuldeep Singh"'
Search Results
2. Assessing the impact of COVID-19 management on the workload of human resources working in India’s National Tuberculosis Elimination Program
- Author
-
Mergenthaler, Christina, Bhatnagar, Aarushi, Dong, Di, Kumar, Vimal, Lakis, Chantale, Mutasa, Ronald, Dapkekar, Shankar, Sahore, Agrima, Surendran, Sapna, Fritsche, Gyorgy, Sachdeva, Kuldeep Singh, and Dieleman, Marjolein
- Published
- 2024
- Full Text
- View/download PDF
3. Active case finding for tuberculosis in India: A syntheses of activities and outcomes reported by the national tuberculosis elimination programme
- Author
-
Nagaraja, Sharath Burugina, Thekkur, Pruthu, Satyanarayana, Srinath, Tharyan, Prathap, Sagili, Karuna D, Tonsing, Jamhoih, Rao, Raghuram, and Sachdeva, Kuldeep Singh
- Published
- 2021
4. Building communities of practice through case-based e-learning to prevent and manage TB among people living with HIV–India
- Author
-
Agarwal, Reshu, Agarwal, Upasna, Das, Chinmoyee, Reddy, Ramesh Allam, Pant, Rashmi, Ho, Christine, Kumar, B. Ravi, Dabla, Vandana, Moonan, Patrick K., Nyendak, Melissa, Anand, Sunil, Puri, Anoop Kumar, Mattoo, Sanjay K., Sachdeva, Kuldeep Singh, Yeldandi, Vijay V., and Sarin, Rohit
- Published
- 2022
- Full Text
- View/download PDF
5. Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets
- Author
-
Sahu, Suvanand, Ditiu, Lucica, Sachdeva, Kuldeep Singh, and Zumla, Alimuddin
- Published
- 2021
- Full Text
- View/download PDF
6. 75th National Conference of tuberculosis and chest diseases: DR KS Sachdeva Speech
- Author
-
Sachdeva, Kuldeep Singh
- Published
- 2021
- Full Text
- View/download PDF
7. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial
- Author
-
Solomon, Sunil Suhas, Quinn, Thomas C., Solomon, Suniti, McFall, Allison M., Srikrishnan, Aylur K., Verma, Vinita, Kumar, Muniratnam S., Laeyendecker, Oliver, Celentano, David D., Iqbal, Syed H., Anand, Santhanam, Vasudevan, Canjeevaram K., Saravanan, Shanmugam, Thomas, David L., Sachdeva, Kuldeep Singh, Lucas, Gregory M., and Mehta, Shruti H.
- Published
- 2020
- Full Text
- View/download PDF
8. Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial
- Author
-
Solomon, Sunil S, Solomon, Suniti, McFall, Allison M, Srikrishnan, Aylur K, Anand, Santhanam, Verma, Vinita, Vasudevan, Canjeevaram K, Balakrishnan, Pachamuthu, Ogburn, Elizabeth L, Moulton, Lawrence H, Kumar, Muniratnam S, Sachdeva, Kuldeep Singh, Laeyendecker, Oliver, Celentano, David D, Lucas, Gregory M, and Mehta, Shruti H
- Published
- 2019
- Full Text
- View/download PDF
9. Assessing tuberculosis control priorities in high-burden settings: a modelling approach
- Author
-
Vesga, Juan F, Hallett, Timothy B, Reid, Michael J A, Sachdeva, Kuldeep Singh, Rao, Raghuram, Khaparde, Sunil, Dave, Paresh, Rade, Kiran, Kamene, Maureen, Omesa, Eunice, Masini, Enos, Omale, Newton, Onyango, Elizabeth, Owiti, Philip, Karanja, Muthoni, Kiplimo, Richard, Alexandru, Sofia, Vilc, Valentina, Crudu, Valeriu, Bivol, Stela, Celan, Cristina, and Arinaminpathy, Nimalan
- Published
- 2019
- Full Text
- View/download PDF
10. A Retrospective Study of Characteristics of HIV Infected Individuals Opting Out from Antiretroviral Treatment under National Programme
- Author
-
Ghate Manisha, Zirpe Sunil, Shidhaye Pallavi, Gurav Shraddha, Rao Amrita, Verma Vinita, Bamrotiya Manish, Sachdeva Kuldeep Singh, Gupta Radhey Shyam, and Gangakhedkar Raman
- Subjects
HIV ,AIDS ,ART Center ,opted out ,Medicine ,Medicine (General) ,R5-920 - Abstract
Background: Retention in care is important for optimal treatment outcomes and effective positive prevention. Reports from India and other countries have mentioned various factors affecting retention but the data on 'opting out' from Antiretroviral Treatment (ART) under the National AIDS Control Programme are scanty. Aim and Objectives: To estimate prevalence and predictors for opting out from Antiretroviral Treatment among HIV infected individuals attending ART center at ICMR-National AIDS Research Institute, Pune. Material and Methods: In this retrospective study, records of individuals taking ART between January 2006 and May 2017 were reviewed. An individual who no longer wished to continue treatment with the national programme because of his/her personal choice and stopped visiting the centre was reported as being 'opted out' from the programme. Results: Of the total 3842 individuals ever initiated on ART, 115 (3%) individuals opted out. The possibility of opting out from ART was 4.9 [95% CI: 1.78-13.6, (p=0.002)] times more in individuals who showed declining trend in their CD4 counts and 8.8 [95% CI: 3.33-23.27,(p
- Published
- 2019
11. Innovatively addressing the challenge of maintaining binocular microscopes under Tuberculosis Programme in India – Is this feasible?
- Author
-
Chadha, Sarabjit, Nagaraja, Sharath Burugina, Prasad, Banaru Muralidhara, Kelamane, Santosha, Satyanarayana, Srinath, and Sachdeva, Kuldeep Singh
- Published
- 2016
- Full Text
- View/download PDF
12. Tuberculosis treatment in the private healthcare sector in India: an analysis of recent trends and volumes using drug sales data
- Author
-
Arinaminpathy, Nimalan, Batra, Deepak, Maheshwari, Nilesh, Swaroop, Kishan, Sharma, Lokesh, Sachdeva, Kuldeep Singh, Khaparde, Sunil, Rao, Raghuram, Gupta, Devesh, Vadera, Bhavin, Nair, Sreenivas A., Rade, Kiran, Kumta, Sameer, and Dewan, Puneet
- Published
- 2019
- Full Text
- View/download PDF
13. Strategies to detect and manage latent tuberculosis infection among household contacts of pulmonary TB patients in high TB burden countries - a systematic review and meta-analysis.
- Author
-
Sagili, Karuna Devi, Muniyandi, Malaisamy, Shringarpure, Kalpita, Singh, Kavita, Kirubakaran, Richard, Rao, Raghuram, Tonsing, Jamhoih, Sachdeva, Kuldeep Singh, Tharyan, Prathap, Sagili, Karuna D, and Muniyandi, M
- Subjects
TUBERCULOSIS diagnosis ,DRUG therapy for tuberculosis ,META-analysis ,SYSTEMATIC reviews ,RESEARCH funding - Abstract
Objective: To summarise latent tuberculosis infection (LTBI) management strategies among household contacts of bacteriologically confirmed pulmonary tuberculosis (TB) patients in high-TB burden countries.Methods: PubMed/MEDLINE (NCBI) and Scopus were searched (January 2006 to December 2021) for studies reporting primary data on LTBI management. Study selection, data management and data synthesis were protocol-driven (PROSPERO-CRD42021208715). Primary outcomes were the proportions of LTBI, initiating and completing tuberculosis preventive treatment (TPT). Reported factors influencing the LTBI care cascade were qualitatively synthesised.Results: From 3694 unique records retrieved, 58 studies from 23 countries were included. Most identified contacts were screened (median 99%, interquartile range [IQR] 82%-100%; 46 studies). Random-effects meta-analysis yielded pooled proportions for: LTBI 41% (95% confidence interval [CI] 33%-49%; 21,566 tested contacts); TPT initiation 91% (95% CI 79%-97%; 129,573 eligible contacts, 34 studies); TPT completion 65% (95% CI 54%-74%; 108,679 TPT-initiated contacts, 28 studies). Heterogeneity was significant (I2 ≥ 95%-100%) and could not be explained in subgroup analyses. Median proportions (IQR) were: LTBI 44% (28%-59%); TPT initiation 86% (60%-100%); TPT completion 68% (44%-82%). Nine broad themes related to diagnostic testing, health system structure and functions, risk perception, documentation and adherence were considered likely to influence the LTBI care cascade.Conclusion: The proportions of household contacts screened, detected with LTBI and initiated on TPT, though variable was high, but the proportions completing TPT were lower indicating current strategies used for LTBI management in high TB burden countries are not sufficient. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?
- Author
-
Sharath Burugina Nagaraja, Srinath Satyanarayana, Sarabjit Singh Chadha, Santosha Kalemane, Jyoti Jaju, Shanta Achanta, Kishore Reddy, Vishnu Potharaju, Srinivas Rao Motta Shamrao, Puneet Dewan, Zachariah Rony, Shailaja Tetali, Raghupathi Anchala, Nanda Kishore Kannuri, Anthony David Harries, and Sachdeva Kuldeep Singh
- Subjects
Medicine ,Science - Abstract
SETTING: Seven districts in Andhra Pradesh, South India. OBJECTIVES: To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). DESIGN: Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009. RESULTS: There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success. CONCLUSION: Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.
- Published
- 2011
- Full Text
- View/download PDF
15. Closing the gaps in tuberculosis detection—considerations for policy makers
- Author
-
Sachdeva, Kuldeep Singh and Kumar, Nishant
- Published
- 2023
- Full Text
- View/download PDF
16. Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016.
- Author
-
Tamilzhalagan, Sembulingam, Shanmugam, Sivakumar, Selvaraj, Ashok, Suba, Sakthi, Suganthi, Chittibabu, Moonan, Patrick K., Surie, Diya, Sathyanarayanan, Mukesh Kumar, Gomathi, Narayanan Shivaram, Jayabal, Lavanya, Sachdeva, Kuldeep Singh, Selvaraju, Sriram, Swaminathan, Soumya, Tripathy, Srikanth Prasad, Hall, Patricia J., and Ranganathan, Uma Devi
- Subjects
PYRAZINAMIDE ,NUCLEOTIDE sequencing ,WHOLE genome sequencing ,ISONIAZID ,RIFAMPIN ,GENETIC mutation ,TUBERCULOSIS ,PHENOTYPES - Abstract
India has a high burden of drug-resistant tuberculosis (DR TB) and many cases go undetected by current drug susceptibility tests (DSTs). This study was conducted to identify rifampicin (RIF) and isoniazid (INH) resistance associated genetic mutations undetected by current clinical diagnostics amongst persons with DR TB in Chennai, India. Retrospectively stored 166 DR TB isolates during 2013–2016 were retrieved and cultured in Löwenstein-Jensen medium. Whole genome sequencing (WGS) and MGIT DST for RIF and INH were performed. Discordant genotypic and phenotypic sensitivity results were repeated for confirmation and the discrepant results considered final. Further, drug resistance-conferring mutations identified through WGS were analyzed for their presence as targets in current WHO-recommended molecular diagnostics. WGS detected additional mutations for rifampicin and isoniazid resistance than WHO-endorsed line probe assays. For RIF, WGS was able to identify an additional 10% (15/146) of rpoB mutant isolates associated with borderline rifampicin resistance compared to MGIT DST. WGS could detect additional DR TB cases than commercially available and WHO-endorsed molecular DST tests. WGS results reiterate the importance of the recent WHO revised critical concentrations of current MGIT DST to detect low-level resistance to rifampicin. WGS may help inform effective treatment selection for persons at risk of, or diagnosed with, DR TB. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Evolutionary journey of programmatic services and treatment outcomes among drug resistant tuberculosis (DR-TB) patients under National TB Elimination Programme in India (2005-2020).
- Author
-
Sachdeva, Kuldeep Singh, Parmar, Malik, Patel, Yogesh, Gupta, Ritu, Rathod, Sandeep, Chauhan, Sandeep, Anand, Sridhar, and Ramachandran, Ranjani
- Published
- 2021
- Full Text
- View/download PDF
18. Evaluation of key survey components of bio-behavioral surveillance among HIV high-risk subpopulation in Western India.
- Author
-
Brahme, Radhika, Godbole, Sheela, Gangakhedkar, Raman, Sachdeva, Kuldeep, Verma, Vinita, Risbud, Arun, Brahme, Radhika G, Godbole, Sheela V, Gangakhedkar, Raman R, Sachdeva, Kuldeep Singh, and Risbud, Arun R
- Published
- 2019
- Full Text
- View/download PDF
19. Insights in Tuberculosis Immunology: Role of NKT and T Regulatory Cells.
- Author
-
Pandey, Pooja, Bhatnagar, Anuj Kumar, Mohan, Anant, Sachdeva, Kuldeep Singh, Vajpayee, Madhu, Das, Bimal Kumar, Samantaray, Jyotish Chandra, Guleria, Randeep, and Singh, Urvashi Balbir
- Abstract
Background: Tuberculosis(TB) control is challenging due to poor drug compliance and emerging resistance. The need of the hour is to determine the prediction of disease cure and relapse. Patients’ immune response is crucial to the disease outcome. This study was designed to study the immune profile of TB patients during treatment and cure. Methods: The cross‑sectional study included newly diagnosed pulmonary TB patients and healthy controls. Levels of serum cytokines/chemokines (Th1/Th2/Th17) were measured by BD cytometric bead array. The cell surface markers assessed in the study were CD3, CD4, CD8, CD16, CD56, and BD human regulatory T cell cocktail (CD4/CD25/CD127). Results: Data analysis observed statistically significant differences in CD3dim/CD56 + natural killer T (NKT) among TB patients with significantly low levels in healthy controls and after treatment completion (P < 0.0001). The analysis also revealed a high percentage of CD3dim/CD56 + NKT in fast responders. The percentage of T regulatory was found to be high in patients when compared with healthy controls; the values were statistically significant (0.0002). Interleukin‑6 was significantly associated with the disease (P < 0.0485). Discussion: A comprehensive understanding of role of CD3dim/CD56+ NKT in antimycobacterial immunity may enable new possibilities for NK cell‑based prophylactic and/or therapeutic strategies against TB. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. TB free India by 2025: hype or hope.
- Author
-
Sachdeva, Kuldeep Singh
- Published
- 2021
- Full Text
- View/download PDF
21. New Vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - 'Reaching the un-reached'
- Author
-
Sachdeva, Kuldeep Singh, Kumar, Ashok, Dewan, Puneet, Kumar, Ajay, and Satyanarayana, Srinath
- Subjects
Government Programs ,DOTS ,tuberculosis ,Urban Population ,Health Personnel ,Tuberculosis, Multidrug-Resistant ,Humans ,India ,Review Article ,multi drug resistance ,RNTCP ,universal access - Abstract
The Phase II (2006-2012) of the Revised National Tuberculosis Control Programme (RNTCP) has been successful in achieving its objectives. Tuberculosis (TB) disease burden (prevalence and mortality) in India has reduced significantly when compared to 1990 levels, and India is on track to achieve the TB related millennium development goals. Despite significant progress, TB still continues to be one of the major public health problems in the country, and intensified efforts are required to reduce TB transmission and accelerate reductions in TB incidence, particularly in urban areas and difficult terrains. Achieving 'Universal access' is possible and necessary for the country. RNTCP during the 12 th Five Year Plan (2012-2017) aims to achieve 'Universal access' to quality assured TB diagnosis and treatment and elaborate plans are being made. This requires broad and concerted efforts and support from all stakeholders with substantial enhancement of commitment and financing at all levels. This paper describes the new vision of RNTCP and an overview of how this will be achieved.
- Published
- 2012
22. What would it cost to scale-up private sector engagement efforts for tuberculosis care? Evidence from three pilot programs in India.
- Author
-
Deo, Sarang, Jindal, Pankaj, Gupta, Devesh, Khaparde, Sunil, Rade, Kiran, Sachdeva, Kuldeep Singh, Vadera, Bhavin, Shah, Daksha, Patel, Kamlesh, Dave, Paresh, Chopra, Rishabh, Jha, Nita, Papineni, Sirisha, Vijayan, Shibu, and Dewan, Puneet
- Subjects
ACTIVITY-based costing ,PRIVATE sector ,COST structure ,ECONOMIC policy ,MONETARY incentives - Abstract
Background: Private providers dominate health care in India and provide most tuberculosis (TB) care. Yet efforts to engage private providers were viewed as unsustainably expensive. Three private provider engagement pilots were implemented in Patna, Mumbai and Mehsana in 2014 based on the recommendations in the National Strategic Plan for TB Control, 2012–17. These pilots sought to improve diagnosis and treatment of TB and increase case notifications by offering free drugs and diagnostics for patients who sought care among private providers, and monetary incentives for providers in one of the pilots. As these pilots demonstrated much higher levels of effectiveness than previously documented, we sought to understand program implementation costs and predict costs for their national scale-up. Methods and findings: We developed a common cost structure across these three pilots comprising fixed and variable cost components. We conducted a retrospective, activity-based costing analysis using programmatic data and qualitative interviews with the respective program managers. We estimated the average recurring costs per TB case at different levels of program scale for the three pilots. We used these cost estimates to calculate the budget required for a national scale up of such pilots. The average cost per privately-notified TB case for Patna, Mumbai and Mehsana was estimated to be US$95, US$110 and US$50, respectively, in May 2016 when these pilots were estimated to cover 50%, 36% and 100% of the total private TB patients, respectively. For Patna and Mumbai pilots, the average cost per case at full scale, i.e. 100% coverage of private TB patients, was projected to be US$91 and US$101, respectively. In comparison, the national TB program’s budget for 2015 averages out to $150 per notified TB case. The total annual additional budget for a national scale up of these pilots was estimated to be US$267 million. Conclusions: As India seeks to eliminate TB, extensive national engagement of private providers will be required. The cost per privately-notified TB case from these pilots is comparable to that already being spent by the public sector and to the projected cost per privately-notified TB case required to achieve national scale-up of these pilots. With additional funds expected to execute against national TB elimination commitments, the scale-up costs of these operationally viable and effective private provider engagement pilots are likely to be financially viable. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Tuberculosis in BRICS: challenges and opportunities for leadership within the post-2015 agenda
- Author
-
Creswell, Jacob, Sahu, Suvanand, Sachdeva, Kuldeep Singh, Ditiu, Lucica, Barreira, Draurio, Mariandyshev, Andrei, Mingting, Chen, and Pillay, Yogan
- Subjects
South Africa -- Health aspects ,Russia -- Health aspects ,Brazil -- Health aspects ,China -- Health aspects ,India -- Health aspects ,Tuberculosis -- Control ,Medical case management -- Forecasts and trends ,Market trend/market analysis ,Health - Abstract
Tuberculosis is a disease of poverty that claims the lives of over a million people annually. (1) Globally, tuberculosis is concentrated in low- to middle-income countries. The five countries--Brazil, the [...]
- Published
- 2014
- Full Text
- View/download PDF
24. Developing a model to predict unfavourable treatment outcomes in patients with tuberculosis and human immunodeficiency virus co-infection in Delhi, India.
- Author
-
Madan, Chandravali, Chopra, Kamal Kishore, Satyanarayana, Srinath, Surie, Diya, Chadha, Vineet, Sachdeva, Kuldeep Singh, Khanna, Ashwani, Deshmukh, Rajesh, Dutta, Lopamudra, Namdeo, Amit, Shukla, Ajay, Sagili, Karuna, and Chauhan, Lakhbir Singh
- Subjects
TUBERCULOSIS ,HIV infections ,AIDS ,LOGISTIC regression analysis ,IMMUNOLOGICAL deficiency syndromes ,SEXUALLY transmitted diseases - Abstract
Background: Tuberculosis (TB) patients with human immunodeficiency virus (HIV) co-infection have worse TB treatment outcomes compared to patients with TB alone. The distribution of unfavourable treatment outcomes differs by socio-demographic and clinical characteristics, allowing for early identification of patients at risk. Objective: To develop a statistical model that can provide individual probabilities of unfavourable outcomes based on demographic and clinical characteristics of TB-HIV co-infected patients. Methodology: We used data from all TB patients with known HIV-positive test results (aged ≥15 years) registered for first-line anti-TB treatment (ATT) in 2015 under the Revised National TB Control Programme (RNTCP) in Delhi, India. We included variables on demographics and pre-treatment clinical characteristics routinely recorded and reported to RNTCP and the National AIDS Control Organization. Binomial logistic regression was used to develop a statistical model to estimate probabilities of unfavourable TB treatment outcomes (i.e., death, loss to follow-up, treatment failure, transfer out of program, and a switch to drug-resistant regimen). Results: Of 55,260 TB patients registered for ATT in 2015 in Delhi, 928 (2%) had known HIV-positive test results. Of these, 816 (88%) had drug-sensitive TB and were ≥15 years. Among 816 TB-HIV patients included, 157 (19%) had unfavourable TB treatment outcomes. We developed a model for predicting unfavourable outcomes using age, sex, disease classification (pulmonary versus extra-pulmonary), TB treatment category (new or previously treated case), sputum smear grade, known HIV status at TB diagnosis, antiretroviral treatment at TB diagnosis, and CD4 cell count at ATT initiation. The chi-square p-value for model calibration assessed using the Hosmer-Lemeshow test was 0.15. The model discrimination, measured as the area under the receiver operator characteristic (ROC) curve, was 0.78. Conclusion: The model had good internal validity, but should be validated with an independent cohort of TB-HIV co-infected patients to assess its performance before clinical or programmatic use. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement.
- Author
-
Parmar, Malik M., Sachdeva, Kuldeep Singh, Dewan, Puneet K., Rade, Kiran, Nair, Sreenivas A., Pant, Rashmi, and Khaparde, Sunil D.
- Subjects
- *
HEALTH policy , *MULTIDRUG-resistant tuberculosis , *PUBLIC health , *SPUTUM examination , *RETROSPECTIVE studies , *PREVENTION , *THERAPEUTICS - Abstract
Background: Globally, India has the world’s highest burden of multidrug-resistant tuberculosis (MDR-TB). Programmatic Management of Drug Resistant TB (PMDT) in India began in 2007 and nationwide coverage was achieved in early 2013. Poor initial microbiological outcomes under the Revised National Tuberculosis Control Programme (RNTCP) prompted detailed analysis. This is the first study on factors significantly associated with poor outcomes in MDR-TB patients treated under the RNTCP. Objective: To evaluate initial sputum culture conversion, culture reversion and final treatment outcomes among MDR-TB patients registered in India from 2007 to early 2011 who were treated with a standard 24-month regimen under daily-observed treatment. Methods: This is a retrospective cohort study. Clinical and microbiological data were abstracted from PMDT records. Initial sputum culture conversion, culture reversion and treatment outcomes were defined by country adaptation of the standard WHO definitions (2008). Cox proportional hazards modeling with logistic regression, multinomial logistic regression and adjusted odds ratio was used to evaluate factors associated with interim and final outcomes respectively, controlling for demographic and clinical characteristics. Results: In the cohort of 3712 MDR-TB patients, 2735 (73.6%) had initial sputum culture conversion at 100 median days (IQR 92–125), of which 506 (18.5%) had culture reversion at 279 median days (IQR 202–381). Treatment outcomes were available for 2264 (60.9%) patients while 1448 (39.0%) patients were still on treatment or yet to have a definite outcome at the time of analysis. Of 2264 patients, 781 (34.5%) had treatment success, 644 (28.4%) died, 670 (29.6%) were lost to follow up, 169 (7.5%) experienced treatment failure or were changed to XDR-TB treatment. Factors significantly associated with either culture non-conversion, culture reversion and/or unfavorable treatment outcomes were baseline BMI < 18; ≥ seven missed doses in intensive phase (IP) and continuation phase (CP); cavitary disease; prior treatment episodes characterized by re-treatment regimen taken twice, longer duration and more episodes of treatment; any weight loss during treatment; males and additional resistance to first line drugs (Ethambutol, Streptomycin). In a subgroup of 104 MDR-TB patients, 62 (59.6%) had Ofloxacin resistance among whom only 25.8% had treatment success, half of the success (54.8%) seen in Ofloxacin sensitive patients. Baseline susceptibility to Ofloxacin (HR 2.04) and Kanamycin (HR 4.55) significantly doubled and quadrupled the chances for culture conversion respectively while baseline susceptibility to Ofloxacin (AOR 0.37) also significantly reduced the odds of unfavorable treatment outcomes (p value ≤0.05) in multinomial logistic regression model. Conclusion: India’s initial MDR-TB patients’ cohort treated under the RNTCP experienced poor treatment outcomes. To address the factors associated with poor treatment outcomes revealed in our study, a systematic multi-pronged approach would be needed. A series of policies and interventions have been developed to address these factors to improve DR-TB treatment outcomes and are being scaled-up in India. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.
- Author
-
Khaparde, Sunil, Raizada, Neeraj, Nair, Sreenivas Achuthan, Denkinger, Claudia, Sachdeva, Kuldeep Singh, Paramasivan, Chinnambedu Nainarappan, Salhotra, Virender Singh, Vassall, Anna, and Hoog, Anja van't
- Subjects
TUBERCULOSIS diagnosis ,RIFAMPIN ,DRUG resistance ,ECONOMIC research ,MYCOBACTERIAL diseases - Abstract
Background: India is considering the scale-up of the Xpert MTB/RIF assay for detection of tuberculosis (TB) and rifampicin resistance. We conducted an economic analysis to estimate the costs of different strategies of Xpert implementation in India. Methods: Using a decision analytical model, we compared four diagnostic strategies for TB patients: (i) sputum smear microscopy (SSM) only; (ii) Xpert as a replacement for the rapid diagnostic test currently used for SSM-positive patients at risk of drug resistance (i.e. line probe assay (LPA)); (iii) Upfront Xpert testing for patients at risk of drug resistance; and (iv) Xpert as a replacement for SSM for all patients. Results: The total costs associated with diagnosis for 100,000 presumptive TB cases were: (i) US$ 619,042 for SSM-only; (ii) US$ 575,377 in the LPA replacement scenario; (iii) US$ 720,523 in the SSM replacement scenario; and (iv) US$ 1,639,643 in the Xpert-for-all scenario. Total cohort costs, including treatment costs, increased by 46% from the SSM-only to the Xpert-for-all strategy, largely due to the costs associated with second-line treatment of a higher number of rifampicin-resistant patients due to increased drug-resistant TB (DR-TB) case detection. The diagnostic costs for an estimated 7.64 million presumptive TB patients would comprise (i) 19%, (ii) 17%, (iii) 22% and (iv) 50% of the annual TB control budget. Mean total costs, expressed per DR-TB case initiated on treatment, were lowest in the Xpert-for-all scenario (US$ 11,099). Conclusions: The Xpert-for-all strategy would result in the greatest increase of TB and DR-TB case detection, but would also have the highest associated costs. The strategy of using Xpert only for patients at risk for DR-TB would be more affordable, but would miss DR-TB cases and the cost per true DR-TB case detected would be higher compared to the Xpert-for-all strategy. As such expanded Xpert strategy would require significant increased TB control budget to ensure that increased case detection is followed by appropriate care. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.
- Author
-
Nair, Sreenivas Achuthan, Raizada, Neeraj, Sachdeva, Kuldeep Singh, Denkinger, Claudia, Schumacher, Samuel, Dewan, Puneet, Kulsange, Shubhangi, Boehme, Catharina, Paramsivan, Chinnambedu Nainarappan, and Arinaminpathy, Nimalan
- Subjects
TUBERCULOSIS patients ,RIFAMPIN ,DRUG resistance ,PUBLIC health ,RETROSPECTIVE studies - Abstract
Background: Tuberculosis remains a major public health challenge for India. Various studies have documented different levels of TB and multi-drug resistant (MDR) TB among diverse groups of the population. In view of renewed targets set under the End TB strategy by 2035, there is an urgent need for TB diagnosis to be strengthened. Drawing on data from a recent, multisite study, we address key questions for TB diagnosis amongst symptomatics presenting for care: are there subgroups of patients that are more likely than others, to be positive for TB? In turn, amongst these positive cases, are there factors—apart from treatment history—that may be predictive for multi-drug resistance? Methods: We used data from a multi-centric prospective demonstration study, conducted from March 2012 to December 2013 in 18 sub-district level TB programme units (TUs) in India and covering a population of 8.8 million. In place of standard diagnostic tests, upfront Xpert MTB/RIF testing was offered to all presumptive TB symptomatics. Here, using data from this study, we used logistic regression to identify association between risk factors and TB and Rifampicin-Resistant TB among symptomatics enrolled in the study. Results: We find that male gender; history of TB treatment; and adult age compared with either children or the elderly are risk factors associated with high TB detection amongst symptomatics, across the TUs. While treatment history is found be a significant risk factor for rifampicin-resistant TB, elderly (65+ yrs) people have significantly lower risk than other age groups. However, pediatric TB cases have no less risk of rifampicin resistance as compared with adults (OR 1.23 (95% C.I. 0.85–1.76)). Similarly, risk of rifampicin resistance among both the genders was the same. These patterns applied across the study sites involved. Notably in Mumbai, amongst those patients with microbiological confirmation of TB, female patients showed a higher risk of having MDR-TB than male patients. Conclusion: Our results cast fresh light on the characteristics of symptomatics presenting for care who are most likely to be microbiologically positive for TB, and for rifampicin resistance. The challenges posed by TB control are complex and multifactorial: evidence from diverse sources, including retrospective studies such as that addressed here, can be invaluable in informing future strategies to accelerate declines in TB burden. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.
- Author
-
Raizada, Neeraj, Sachdeva, Kuldeep Singh, Swaminathan, Soumya, Kulsange, Shubhangi, Khaparde, Sunil D., Nair, Sreenivas Achuthan, Khanna, Ashwani, Chopra, Kamal Kishore, Hanif, Mahmud, Sethi, Gulshan Rai, Umadevi, K. R., Keshav Chander, G., Saha, Brojakishore, Shah, Amar, Parmar, Malik, Ghediya, Mayank, Jaju, Jyoti, Boehme, Catharina, and Paramasivan, Chinnambedu Nainarappan
- Subjects
- *
DIAGNOSTIC specimens , *PEDIATRICS , *RIFAMPIN , *DRUG resistance , *LUNG diseases - Abstract
Background: India accounts for one-fifth of the global TB incidence. While the exact burden of childhood TB is not known, TB remains one of the leading causes of childhood mortality in India. Bacteriological confirmation of TB in children is challenging due to difficulty in obtaining quality specimens, in the absence of which diagnosis is largely based on clinical judgement. While testing multiple specimens can potentially contribute to higher proportion of laboratory confirmed paediatric TB cases, lack of high sensitivity tests adds to the diagnostic challenge. We describe here our experiences in piloting upfront Xpert MTB/RIF testing, for diagnosis of TB in paediatric population in respiratory and extra pulmonary specimens, as recently recommended by WHO. Method: Xpert MTB/RIF testing was offered to all paediatric (0–14 years) presumptive TB cases (both pulmonary and extra-pulmonary) seeking care at public and private health facilities in the project areas covering 4 cities of India. Results: Under this pilot project, 8,370 paediatric presumptive TB & presumptive DR-TB cases were tested between April and–November 2014. Overall, 9,149 specimens were tested, of which 4,445 (48.6%) were non-sputum specimens. Xpert MTB/RIF gave 9,083 (99.2%, CI 99.0–99.4) valid results. Of the 8,143 presumptive TB cases enrolled, 517 (6.3%, CI 5.8–6.9) were bacteriologically confirmed. TB detection rates were two fold higher with Xpert MTB/RIF as compared to smear microscopy. Further, a total of 60 rifampicin resistant TB cases were detected, of which 38 were detected among 512 presumptive TB cases while 22 were detected amongst 227 presumptive DR-TB cases tested under the project. Conclusion: Xpert MTB/RIF with advantages of quick turnaround testing-time, high proportion of interpretable results and feasibility of rapid rollout, substantially improved the diagnosis of bacteriologically confirmed TB in children, while simultaneously detecting rifampicin resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India.
- Author
-
Deshmukh, Rajesh D., Dhande, D. J., Sachdeva, Kuldeep Singh, Sreenivas, Achuthan, Kumar, A. M. V., Satyanarayana, Srinath, Parmar, Malik, Moonan, Patrick K., and Lo, Terrence Q.
- Subjects
TUBERCULOSIS patients ,MULTIDRUG-resistant tuberculosis ,FOLLOW-up studies (Medicine) ,MEDICAL centers ,THERAPEUTICS - Abstract
Introduction: Multidrug-resistant Tuberculosis (MDR TB) is emerging public health concern globally. Lost to follow-up (LTFU) is one of the key challenge in MDRTB treatment. In 2013, 18% of MDR TB patients were reported LTFU in India. A qualitative study was conducted to obtain better understanding of both patient and provider related factors for LTFU among MDR TB treatment. Methods: Qualitative semi-structured personal interviews were conducted with 20 MDRTB patients reported as LTFU and 10 treatment providers in seven districts linked to Nagpur Drug resistant TB Centre (DRTBC) during August 2012–February 2013. Interviews were transcribed and inductive content analysis was performed to derive emergent themes. Results: We found multiple factors influencing MDR TB treatment adherence. Barriers to treatment adherence included drug side effects, a perceived lack of provider support, patient financial constraints, conflicts with the timing of treatment services, alcoholism and social stigma. Conclusions: Patient adherence to treatment is multi-factorial and involves individual patient factors, provider factors, and community factors. Addressing issue of LTFU during MDRTB treatment requires enhanced efforts towards resolving medical problems like adverse drug effects, developing short duration treatment regimens, reducing pill burden, motivational counselling, flexible timings for DOT services, social, family support for patients & improving awareness about disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. The Potential Impact of Up-Front Drug Sensitivity Testing on India’s Epidemic of Multi-Drug Resistant Tuberculosis.
- Author
-
Sachdeva, Kuldeep Singh, Raizada, Neeraj, Gupta, Radhey Shyam, Nair, Sreenivas Achuthan, Denkinger, Claudia, Paramasivan, Chinnambedu Nainarappan, Kulsange, Shubhangi, Thakur, Rahul, Dewan, Puneet, Boehme, Catharina, and Arinaminpathy, Nimalan
- Subjects
- *
PHARMACODYNAMICS , *EPIDEMIOLOGY , *MULTIDRUG resistance , *TUBERCULOSIS treatment , *DISEASE susceptibility - Abstract
Background: In India as elsewhere, multi-drug resistance (MDR) poses a serious challenge in the control of tuberculosis (TB). The End TB strategy, recently approved by the world health assembly, aims to reduce TB deaths by 95% and new cases by 90% between 2015 and 2035. A key pillar of this approach is early diagnosis of tuberculosis, including use of higher-sensitivity diagnostic testing and universal rapid drug susceptibility testing (DST). Despite limitations of current laboratory assays, universal access to rapid DST could become more feasible with the advent of new and emerging technologies. Here we use a mathematical model of TB transmission, calibrated to the TB epidemic in India, to explore the potential impact of a major national scale-up of rapid DST. To inform key parameters in a clinical setting, we take GeneXpert as an example of a technology that could enable such scale-up. We draw from a recent multi-centric demonstration study conducted in India that involved upfront Xpert MTB/RIF testing of all TB suspects. Results: We find that widespread, public-sector deployment of high-sensitivity diagnostic testing and universal DST appropriately linked with treatment could substantially impact MDR-TB in India. Achieving 75% access over 3 years amongst all cases being diagnosed for TB in the public sector alone could avert over 180,000 cases of MDR-TB (95% CI 44187 – 317077 cases) between 2015 and 2025. Sufficiently wide deployment of Xpert could, moreover, turn an increasing MDR epidemic into a diminishing one. Synergistic effects were observed with assumptions of simultaneously improving MDR-TB treatment outcomes. Our results illustrate the potential impact of new and emerging technologies that enable widespread, timely DST, and the important effect that universal rapid DST in the public sector can have on the MDR-TB epidemic in India. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.
- Author
-
Sachdeva, Kuldeep Singh, Raizada, Neeraj, Sreenivas, Achuthan, van't Hoog, Anna H., van den Hof, Susan, Dewan, Puneet K., Thakur, Rahul, Gupta, R. S., Kulsange, Shubhangi, Vadera, Bhavin, Babre, Ameet, Gray, Christen, Parmar, Malik, Ghedia, Mayank, Ramachandran, Ranjani, Alavadi, Umesh, Arinaminpathy, Nimalan, Denkinger, Claudia, Boehme, Catharina, and Paramasivan, C. N.
- Subjects
- *
PUBLIC health , *TUBERCULOSIS , *RIFAMPIN , *DRUG resistance , *REGRESSION analysis - Abstract
Background: Xpert MTB/RIF, the first automated molecular test for tuberculosis, is transforming the diagnostic landscape in high-burden settings. This study assessed the impact of up-front Xpert MTB/RIF testing on detection of pulmonary tuberculosis (PTB) and rifampicin-resistant PTB (DR-TB) cases in India. Methods: This demonstration study was implemented in 18 sub-district level TB programme units (TUs) in India in diverse geographic and demographic settings covering a population of 8.8 million. A baseline phase in 14 TUs captured programmatic baseline data, and an intervention phase in 18 TUs had Xpert MTB/RIF offered to all presumptive TB patients. We estimated changes in detection of TB and DR-TB, the former using binomial regression models to adjust for clustering and covariates. Results: In the 14 study TUs, which participated in both phases, 10,675 and 70,556 presumptive TB patients were enrolled in the baseline and intervention phase, respectively, and 1,532 (14.4%) and 14,299 (20.3%) bacteriologically confirmed PTB cases were detected. The implementation of Xpert MTB/RIF was associated with increases in both notification rates of bacteriologically confirmed TB cases (adjusted incidence rate ratio [aIRR] 1.39; CI 1.18-1.64), and proportion of bacteriological confirmed TB cases among presumptive TB cases (adjusted risk ratio (aRR) 1.33; CI 1.6-1.52). Compared with the baseline strategy of selective drug-susceptibility testing only for PTB cases at high risk of drug-resistant TB, Xpert MTB/RIF implementation increased rifampicin resistant TB case detection by over fivefold. Among, 2765 rifampicin resistance cases detected, 1055 were retested with conventional drug susceptibility testing (DST). Positive predictive value (PPV) of rifampicin resistance detected by Xpert MTB/RIF was 94.7% (CI 91.3-98.1), in comparison to conventional DST. Conclusion: Introduction of Xpert MTB/RIF as initial diagnostic test for TB in public health facilities significantly increased case-notification rates of all bacteriologically confirmed TB by 39% and rifampicin-resistant TB case notification by fivefold. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Catching the Missing Million: Experiences in Enhancing TB & DR-TB Detection by Providing Upfront Xpert MTB/RIF Testing for People Living with HIV in India.
- Author
-
Raizada, Neeraj, Sachdeva, Kuldeep Singh, Sreenivas, Achuthan, Kulsange, Shubhangi, Gupta, Radhey Shyam, Thakur, Rahul, Dewan, Puneet, Boehme, Catharina, and Paramsivan, Chinnambedu Nainarappan
- Subjects
- *
HIV-positive persons , *TUBERCULOSIS treatment , *HEALTH facilities , *DRUG resistance in bacteria , *RIFAMPIN - Abstract
Background: A critical challenge in providing TB care to People Living with HIV (PLHIV) is establishing an accurate bacteriological diagnosis. Xpert MTB/RIF, a highly sensitive and specific rapid tool, offers a promising solution in addressing these challenges. This study presents results from PLHIV taking part in a large demonstration study across India wherein upfront Xpert MTB/RIF testing was offered to all presumptive PTB cases in public health facilities. Method: The study covered a population of 8.8 million across 18 sub-district level tuberculosis units (TU), with one Xpert MTB/RIF platform established at each TU. All HIV-infected patients suspected of TB (both TB and Drug Resistant TB (DR-TB)) accessing public health facilities in study area were prospectively enrolled and provided upfront Xpert MTB/RIF testing. Result: 2,787 HIV-infected presumptive pulmonary TB cases were enrolled and 867 (31.1%, 95% Confidence Interval (CI) 29.4‒32.8) HIV-infected TB cases were diagnosed under the study. Overall 27.6% (CI 25.9–29.3) of HIV-infected presumptive PTB cases were positive by Xpert MTB/RIF, compared with 12.9% (CI 11.6–14.1) who had positive sputum smears. Upfront Xpert MTB/RIF testing of presumptive PTB and DR-TB cases resulted in diagnosis of 73 (9.5%, CI 7.6‒11.8) and 16 (11.2%, CI 6.7‒17.1) rifampicin resistance cases, respectively. Positive predictive value (PPV) for rifampicin resistance detection was high 97.7% (CI 89.3‒99.8), with no significant difference with or without prior history of TB treatment. Conclusion: The study results strongly demonstrate limitations of using smear microscopy for TB diagnosis in PLHIV, leading to low TB and DR-TB detection which can potentially lead to either delayed or sub-optimal TB treatment. Our findings demonstrate the usefulness and feasibility of addressing this diagnostic gap with upfront of Xpert MTB/RIF testing, leading to overall strengthening of care and support package for PLHIV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Alarming Levels of Drug-Resistant Tuberculosis in HIV-Infected Patients in Metropolitan Mumbai, India.
- Author
-
Isaakidis, Petros, Das, Mrinalini, Kumar, Ajay M V, Peskett, Christopher, Khetarpal, Minni, Bamne, Arun, Adsul, Balkrishna, Manglani, Mamta, Sachdeva, Kuldeep Singh, Parmar, Malik, Kanchar, Avinash, Rewari, B.B., Deshpande, Alaka, Rodrigues, Camilla, Shetty, Anjali, Rebello, Lorraine, and Saranchuk, Peter
- Subjects
TUBERCULOSIS ,DRUG resistance ,HIV-positive persons ,CROSS-sectional method - Abstract
Background: Drug-resistant tuberculosis (DR-TB) is a looming threat to tuberculosis control in India. However, no countrywide prevalence data are available. The burden of DR-TB in HIV-co-infected patients is likewise unknown. Undiagnosed and untreated DR-TB among HIV-infected patients is a major cause of mortality and morbidity. We aimed to assess the prevalence of DR-TB (defined as resistance to any anti-TB drug) in patients attending public antiretroviral treatment (ART) centers in greater metropolitan Mumbai, India. Methods: A cross-sectional survey was conducted among adults and children ART-center attendees. Smear microscopy, culture and drug-susceptibility-testing (DST) against all first and second-line TB-drugs using phenotypic liquid culture (MGIT) were conducted on all presumptive tuberculosis patients. Analyses were performed to determine DR-TB prevalence and resistance patterns separately for new and previously treated, culture-positive TB-cases. Results: Between March 2013 and January 2014, ART-center attendees were screened during 14135 visits, of whom 1724 had presumptive TB. Of 1724 attendees, 72 (4%) were smear-positive and 202 (12%) had a positive culture for Mycobacterium tuberculosis. Overall DR-TB was diagnosed in 68 (34%, 95% CI: 27%–40%) TB-patients. The proportions of DR-TB were 25% (29/114) and 44% (39/88) among new and previously treated cases respectively. The patterns of DR-TB were: 21% mono-resistant, 12% poly-resistant, 38% multidrug-resistant (MDR-TB), 21% pre-extensively-drug-resistant (MDR-TB plus resistance to either a fluoroquinolone or second-line injectable), 6% extensively drug-resistant (XDR-TB) and 2% extremely drug-resistant TB (XDR-TB plus resistance to any group-IV/V drug). Only previous history of TB was significantly associated with the diagnosis of DR-TB in multivariate models. Conclusion: The burden of DR-TB among HIV-infected patients attending public ART-centers in Mumbai was alarmingly high, likely representing ongoing transmission in the community and health facilities. These data highlight the need to promptly diagnose drug-resistance among all HIV-infected patients by systematically offering access to first and second-line DST to all patients with ‘presumptive TB’ rather than ‘presumptive DR-TB’ and tailor the treatment regimen based on the resistance patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Enhancing TB Case Detection: Experience in Offering Upfront Xpert MTB/RIF Testing to Pediatric Presumptive TB and DR TB Cases for Early Rapid Diagnosis of Drug Sensitive and Drug Resistant TB.
- Author
-
Raizada, Neeraj, Sachdeva, Kuldeep Singh, Nair, Sreenivas Achuthan, Kulsange, Shubhangi, Gupta, Radhey Shayam, Thakur, Rahul, Parmar, Malik, Gray, Christen, Ramachandran, Ranjani, Vadera, Bhavin, Ekka, Shobha, Dhawan, Shikha, Babre, Ameet, Ghedia, Mayank, Alavadi, Umesh, Dewan, Puneet, Khetrapal, Mini, Khanna, Ashwini, Boehme, Catharina, and Paramsivan, Chinnambedu Nainarappan
- Subjects
- *
TUBERCULOSIS diagnosis , *PRESUMPTIVE blood tests (Forensic chemistry) , *DRUG resistance in bacteria , *CLINICAL medicine , *RIFAMPIN - Abstract
Background: Diagnosis of pulmonary tuberculosis (PTB) in children is challenging due to difficulties in obtaining good quality sputum specimens as well as the paucibacillary nature of disease. Globally a large proportion of pediatric tuberculosis (TB) cases are diagnosed based only on clinical findings. Xpert MTB/RIF, a highly sensitive and specific rapid tool, offers a promising solution in addressing these challenges. This study presents the results from pediatric groups taking part in a large demonstration study wherein Xpert MTB/RIF testing replaced smear microscopy for all presumptive PTB cases in public health facilities across India. Methods: The study covered a population of 8.8 million across 18 programmatic sub-district level tuberculosis units (TU), with one Xpert MTB/RIF platform established at each study TU. Pediatric presumptive PTB cases (both TB and Drug Resistant TB (DR-TB)) accessing any public health facilities in study area were prospectively enrolled and tested on Xpert MTB/RIF following a standardized diagnostic algorithm. Results: 4,600 pediatric presumptive pulmonary TB cases were enrolled. 590 (12.8%, CI 11.8–13.8) pediatric PTB were diagnosed. Overall 10.4% (CI 9.5–11.2) of presumptive PTB cases had positive results by Xpert MTB/RIF, compared with 4.8% (CI 4.2–5.4) who had smear-positive results. Upfront Xpert MTB/RIF testing of presumptive PTB and presumptive DR-TB cases resulted in diagnosis of 79 and 12 rifampicin resistance cases, respectively. Positive predictive value (PPV) for rifampicin resistance detection was high (98%, CI 90.1–99.9), with no statistically significant variation with respect to past history of treatment. Conclusion: Upfront access to Xpert MTB/RIF testing in pediatric presumptive PTB cases was associated with a two-fold increase in bacteriologically-confirmed PTB, and increased detection of rifampicin-resistant TB cases under routine operational conditions across India. These results suggest that routine Xpert MTB/RIF testing is a promising solution to present-day challenges in the diagnosis of PTB in pediatric patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Impact of Introducing the Line Probe Assay on Time to Treatment Initiation of MDR-TB in Delhi, India.
- Author
-
Singla, Neeta, Satyanarayana, Srinath, Sachdeva, Kuldeep Singh, Van den Bergh, Rafael, Reid, Tony, Tayler-Smith, Katherine, Myneedu, V. P., Ali, Engy, Enarson, Donald A., Behera, Digamber, and Sarin, Rohit
- Subjects
MULTIDRUG-resistant tuberculosis ,PATIENT management ,RETROSPECTIVE studies ,COHORT analysis ,DIAGNOSIS ,THERAPEUTICS - Abstract
Setting: National Institute of Tuberculosis and Respiratory Diseases (erstwhile Lala Ram Sarup Institute) in Delhi, India. Objectives: To evaluate before and after the introduction of the line Probe Assay (LPA) a) the overall time to MDR-TB diagnosis and treatment initiation; b) the step-by-step time lapse at each stage of patient management; and c) the lost to follow-up rates. Methods: A retrospective cohort analysis was done using data on MDR-TB patients diagnosed during 2009–2012 under Revised National Tuberculosis Control Programme at the institute. Results: Following the introduction of the LPA in 2011, the overall median time from identification of patients suspected for MDR-TB to the initiation of treatment was reduced from 157 days (IQR 127–200) to 38 days (IQR 30–79). This reduction was attributed mainly to a lower diagnosis time at the laboratory. Lost to follow-up rates were also significantly reduced after introduction of the LPA (12% versus 39% pre-PLA). Conclusion: Introduction of the LPA was associated with a major reduction in the delay between identification of patients suspected for MDR-TB and initiation of treatment, attributed mainly to a reduction in diagnostic time in the laboratory. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. LED-Fluorescence Microscopy for Diagnosis of Pulmonary Tuberculosis under Programmatic Conditions in India.
- Author
-
Reza, Lord Wasim, Satyanarayna, Srinath, Enarson, Donald A., Kumar, Ajay M. V., Sagili, Karuna, Kumar, Sujeet, Prabhakar, Levi Anand, Devendrappa, N. M., Pandey, Ashish, Wilson, Nevin, Chadha, Sarabjit, Thapa, Badri, Sachdeva, Kuldeep Singh, and Kohli, Mohan P.
- Subjects
FLUORESCENCE microscopy ,LIGHT emitting diodes ,TUBERCULOSIS ,ZIEHL-Neelsen stain ,MEDICAL schools ,PREVENTIVE medicine - Abstract
Background: Light-emitting diode fluorescence microscopy (LED-FM) has been shown to be more sensitive than conventional bright field microscopy using Ziehl-Neelsen (ZN) stain in detecting sputum smear positive tuberculosis in controlled laboratory conditions. In 2012, Auramine O staining based LED-FM replaced conventional ZN microscopy in 200 designated microscopy centres (DMC) of medical colleges operating in collaboration with India’s Revised National Tuberculosis Control Programme. We aimed to assess the impact of introduction of LED-FM services on sputum smear positive case detection under program conditions. Methods: This was a before and after comparison study. In 15 randomly selected medical college DMCs, all presumptive TB patients who underwent sputum smear examination in the years 2011 (before LED-FM) and 2012 (after LED-FM) were compared. An additional 15 comparable DMCs that implemented conventional ZN sputum smear microscopy were also selected for comparison between 2011 and 2012. Results: The proportion of presumptive TB patients (PTP)found sputum smear positive increased by 30%- from 13.6% (3432/25159) in 2011 to 17.8% (4706/26426) in 2012 (P value <0.01) in the sites that implemented LED-FM microscopy, whereas in DMCs where the ZN staining procedure is followed the proportion of sputum smear positive had remained unchanged (13.0%versus 12.6%;P value0.31). Conclusion: Use of LED-FM significantly increased the proportion of smear positive cases among presumptive TB patients under routine program conditions in high workload laboratories. The study provides operational evidence needed to scale-up the use of LED-FM in similar settings in India and beyond. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
37. Is One Sputum Specimen as Good as Two during Follow-Up Cultures for Monitoring Multi Drug Resistant Tuberculosis Patients in India?
- Author
-
Nagaraja, Sharath Burugina, Kumar, Ajay M. V., Sachdeva, Kuldeep Singh, Ramachandran, Ranjani, Satyanarayana, Srinath, Bansal, Avi, Parmar, Malik, Chadha, Sarabjit, Nair, Sreenivas, Kumar, Ashok, Hinderaker, Sven Gudmund, Edginton, Mary, Dewan, Puneet K., and Pai, Madhukar
- Subjects
SPUTUM ,SALIVA ,CULTURES (Biology) ,BIOLOGY methodology ,MULTIDRUG resistance - Abstract
Background: In India, the Revised National Tuberculosis Control Programme (RNTCP) has adopted the strategy of examining two specimens during follow-up culture examinations to monitor the treatment response of multi-drug resistant tuberculosis (MDR-TB) patients. Objectives: To determine the incremental yield of the second sputum specimen during follow-up culture examinations among patients with MDR-TB and the effect on case management on changing from two to one specimen follow-up strategy. Methods: A cross sectional record review of MDR-TB patients registered during 2008-09 under RNTCP was undertaken in three MDR-TB treatment sites of India. Results: Of 1721 pairs of follow-up sputum culture examinations done among 220 MDR-TB patients, 451(26%) were positive with either of the two specimens; 29(1.7%) were culture positive only on the second specimen indicating the incremental yield. To detect one additional culture positive result on the second specimen, 59 specimens needed to be processed. If we had examined only one specimen, we would have missed 29 culture-positive results. By current RNTCP guidelines, however, a single specimen policy would have altered case management in only 3(0.2%) instances, where patients would have missed a one month extension of the intensive phase of MDR-TB treatment. There is no meaningful advantage in using two specimens for the monitoring of MDR-TB patients. A single specimen policy could be safely implemented with negligible clinical effect on MDR-TB patients and favourable resource implications for RNTCP. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
38. How Did the TB Patients Reach DOTS Services in Delhi? A Study of Patient Treatment Seeking Behavior.
- Author
-
Kapoor, Sunil K., Raman, A. Venkat, Sachdeva, Kuldeep Singh, Satyanarayana, Srinath, and Neyrolles, Olivier
- Subjects
TUBERCULOSIS research ,TUBERCULOSIS patients ,MEDICAL care ,LUNG diseases - Abstract
Setting: Revised National Tuberculosis Control Programme (RNTCP), Delhi, India. Objective: To ascertain the number and sequence of providers visited by TB patients before availing treatment services from DOTS; to describe the duration between onset of symptoms to treatment. Study design: A cross sectional, qualitative study. Information was gathered through in-depth interviews of TB patients registered during the month of Oct, 2012 for availing TB treatment under the Revised National TB Control Programme from four tuberculosis diagnosis and treatment centers in Delhi. Results: Out of the 114 patients who registered, 108 participated in the study. The study showed that informal providers and retail chemists were the first point of contact and source of clinical advice for two-third of the patients, while the rest sought medical care from qualified providers directly. Most patients sought medical care from more than two providers, before being diagnosed as TB. Female TB patients and patients with extra-pulmonary TB had long mean duration between onset of symptoms to initiation of treatment (6.3 months and 8.4 months respectively). Conclusion: The pathways followed by TB patients, illustrated in this study, provide valuable lessons on the importance of different types of providers (both formal and informal) in the health system in a society like India and the delays in the diagnosis and treatment of tuberculosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
39. Operational Challenges in Diagnosing Multi-Drug Resistant TB and Initiating Treatment in Andhra Pradesh, India.
- Author
-
Chadha, Sarabjit S., BN, Sharath, Reddy, Kishore, Jaju, Jyothi, PH, Vishnu, Rao, Sreenivas, Parmar, Malik, Satyanarayana, Srinath, Sachdeva, Kuldeep Singh, Wilson, Nevin, and Harries, Anthony D.
- Subjects
TUBERCULOSIS ,DIAGNOSIS ,DRUG resistance - Abstract
Background: Revised National TB Control Programme (RNTCP), Andhra Pradesh, India. There is limited information on whether MDR-TB suspects are identified, undergo diagnostic assessment and are initiated on treatment according to the programme guidelines. Objectives: To assess i) using the programme definition, the number and proportion of MDR-TB suspects in a large cohort of TB patients on first-line treatment under RNTCP ii) the proportion of these MDR-TB suspects who underwent diagnosis for MDR-TB and iii) the number and proportion of those diagnosed as MDR-TB who were successfully initiated on treatment. Methods: A retrospective cohort analysis, by reviewing RNTCP records and reports, was conducted in four districts of Andhra Pradesh, India, among patients registered for first line treatment during October 2008 to December 2009. Results: Among 23,999 TB patients registered for treatment there were 559 (2%) MDR-TB suspects (according to programme definition) of which 307 (55%) underwent diagnosis and amongst these 169 (55%) were found to be MDR-TB. Of the MDR-TB patients, 112 (66%) were successfully initiated on treatment. Amongst those eligible for MDR-TB services, significant proportions are lost during the diagnostic and treatment initiation pathway due to a variety of operational challenges. The programme needs to urgently address these challenges for effective delivery and utilisation of the MDR-TB services. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
40. Source of Previous Treatment for Re-Treatment TB Cases Registered under the National TB Control Programme, India, 2010.
- Author
-
Sachdeva, Kuldeep Singh, Satyanarayana, Srinath, Dewan, Puneet Kumar, Nair, Sreenivas Achuthan, Reddy, Raveendra, Kundu, Debasish, Chadha, Sarabjit Singh, Venkatachalaiah, Ajay Kumar Madhugiri, and Parmar, Malik
- Subjects
- *
TUBERCULOSIS patients , *TUBERCULOSIS treatment , *TREATMENT programs , *CLINICAL trial registries , *ACQUISITION of data , *DISEASE relapse , *SCIENCE education , *SUPERVISION - Abstract
Background: In 2009, nearly half (289,756) of global re-treatment TB notifications are from India; no nationallyrepresentative data on the source of previous treatment was available to inform strategies for improvement of initial TB treatment outcome. Objectives: To assess the source of previous treatment for re-treatment TB patients registered under India's Revised National TB control Programme (RNTCP). Methodology: A nationally-representative cross sectional study was conducted in a sample of 36 randomly-selected districts. All consecutively registered retreatment TB patients during a defined 15-day period in these 36 districts were contacted and the information on the source of previous treatment sought. Results: Data was collected from all 1712 retreatment TB patients registered in the identified districts during the study period. The data includes information on 595 'relapse' cases, 105 'failure' cases, 437 'treatment after default (TAD)' cases and 575 're-treatment others' cases. The source of most recent previous anti-tuberculosis therapy for 754 [44% (95% CI, 38.2%- 49.9%)] of the re-treatment TB patients was from providers outside the TB control programme. A higher proportion of patients registered as TAD (64%) and 'retreatment others' (59%) were likely to be treated outside the National Programme, when compared to the proportion among 'relapse' (22%) or 'failure' (6%). Extrapolated to national registration, of the 292,972 re-treatment registrations in 2010, 128,907 patients would have been most recently treated outside the national programme. Conclusions: Nearly half of the re-treatment cases registered with the national programme were most recently treated outside the programme setting. Enhanced efforts towards extending treatment support and supervision to patients treated by private sector treatment providers are urgently required to improve the quality of treatment and reduce the numbers of patients with recurrent disease. In addition, reasons for the large number of recurrent TB cases from those already treated by the national programme require urgent detailed investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
41. Facilitators and Barriers for Private Health Sector Engagement for TB Care in India: A Systematic Review and Meta-Synthesis of Qualitative Research.
- Author
-
Ps R, Shannawaz M, Mathew ME, and Sachdeva KS
- Abstract
Introduction: Private sector engagement is recognized as one of the most critical interventions to achieve the End TB goals in India. We conducted a systematic review and a meta-synthesis of qualitative studies to identify the barriers and facilitators for private sector engagement in TB care in India., Methods: A systematic search in electronic databases was done. We assessed the methodological limitations of individual studies, synthesized the evidence using thematic analysis, and assessed our confidence in each finding., Results: Of the 19 eligible articles included for the qualitative synthesis, 31.5% (6/19) were conducted in northern states of India. Included studies had details from 31 focus group discussions and 303 in-depth interviews conducted among various stakeholders. The synthesis revealed that barriers to engaging the private sector were lack of coordination mechanisms, lack of the National TB Elimination Program (NTEP) staff capacity to deal with the private sector, lack of private practitioners' knowledge on various programmatic aspects, and perceived complexity of the data exchange mechanism. The private sector felt that NTEP was not sensitive to the patient's confidentiality and demanded too much patient data. The private sector considered nonfinancial incentives like recognition, feedback, involving them in planning, and giving them equal status in partnership as powerful enablers for their engagement in TB care., Conclusion: Factors related to the context in which the engagement occurs, the architecture of the engagement, and interaction among the actors contribute to barriers to engaging the private sector for TB care in India. Strengthening policies to protect patient confidentiality, using behavior change communication to NTEP program managers, providing managerial and soft-skill training to NTEP staff, promoting nonfinancial incentives to private providers, establishing a coordination mechanism between the sectors, and simplifying the data exchange mechanisms need to be done to further strengthen the private-sector engagement., (© Rakesh PS et al.)
- Published
- 2024
- Full Text
- View/download PDF
42. Test and Treat Model for Tuberculosis Preventive Treatment among Household Contacts of Pulmonary Tuberculosis Patients in Selected Districts of Maharashtra: A Mixed-Methods Study on Care Cascade, Timeliness, and Early Implementation Challenges.
- Author
-
Mahajan P, Soundappan K, Singla N, Mehta K, Nuken A, Thekkur P, Nair D, Rattan S, Thakur C, Sachdeva KS, and Kalottee B
- Abstract
Tuberculosis preventive treatment (TPT) is an important intervention in preventing infection and reducing TB incidence among household contacts (HHCs). A mixed-methods study was conducted to assess the "Test and Treat" model of TPT care cascade among HHCs aged ≥5 years of pulmonary tuberculosis (PTB) patients (bacteriologically/clinically confirmed) being provided TPT care under Project Axshya Plus implemented in Maharashtra (India). A quantitative phase cohort study based on record review and qualitative interviews to understand the challenges and solutions in the TPT care cascade were used. Of the total 4181 index patients, 14,172 HHCs were screened, of whom 36 (0.3%) HHCs were diagnosed with tuberculosis. Among 14,133 eligible HHCs, 10,777 (76.3%) underwent an IGRA test. Of them, 2468 (22.9%) tested positive for IGRA and were suggested for chest X-ray. Of the eligible 2353 HHCs, 2159 (91.7%) were started on TPT, of whom 1958 (90.6%) completed the treatment. The median time between treatment initiation of index PTB patient and (a) HHC screening was 31 days; (b) TPT initiation was 64 days. The challenges in and suggested solutions for improving the TPT care cascade linked to subthemes were tuberculosis infection testing, chest X-ray, human resources, awareness and engagement, accessibility to healthcare facilities, TPT drugs, follow-up, and assessment. A systematic monitoring and time-based evaluation of TPT cascade care delivery followed by prompt corrective actions/interventions could be a crucial strategy for its effective implementation and for the prevention of tuberculosis.
- Published
- 2023
- Full Text
- View/download PDF
43. Patient adherence to tuberculosis treatment in the Indian subcontinent: systematic review and meta-synthesis of qualitative research.
- Author
-
Shringarpure K, Gurumurthy M, Sagili KD, Taylor M, Garner P, Tonsing J, Rao R, and Sachdeva KS
- Subjects
- Humans, Health Personnel, Qualitative Research, Reproducibility of Results, Patient Compliance, Tuberculosis drug therapy
- Abstract
Objectives: How well patients adhere to their tuberculosis (TB) treatment influences their recovery and development of drug resistance, but influences on adherence are multiple and often competing. We synthesised qualitative studies from our setting in the Indian subcontinent to understand the dimensions and dynamics involved to help inform service provision., Design: Qualitative synthesis comprising inductive coding, thematic analysis and forming a conceptual framework., Data Sources: Medline (OVID), Embase (OVID), CINAHL (EBSCOHost), PsycINFO (EBSCOHost), Web of Science Core Collection, Cochrane Library and Epistemonikos were databases searched on 26 March 2020 for studies published since 1 January 2000., Eligibility Criteria for Selecting Studies: We included reports in English from the Indian subcontinent that used qualitative or mixed-methodology designs and reported findings around adherence to TB treatment. Full texts meeting eligibility were sampled based on 'thickness' (the richness of the qualitative data reported)., Data Extraction and Synthesis: Two reviewers used standardised methods to screen abstracts and code. Included studies were assessed for reliability and quality using a standard tool. Qualitative synthesis was performed by inductive coding, thematic analysis and developing conceptual framework., Results: Of 1729 abstracts screened from initial search, 59 were shortlisted for full-text review. Twenty-four studies that qualified as 'thick' were included in the synthesis. Studies were set in India (12), Pakistan (6), Nepal (3), Bangladesh (1) or in two or more of these countries (2). Of the 24 studies, all but one included people who were taking TB treatment (1 study included only healthcare providers), and 17 included healthcare workers, community members or both.We identified three themes: (1) personal influences on the people with TB include interconnections between their social role in the family unit, their own priorities in day-to-day living and their experience to date with the disease; (2) adherence is profoundly influenced by how individual healthcare providers interact with patients on treatment and address their needs; (3) adherence is influenced across communities by structural, social, economic and cultural factors related to treatment., Conclusion: Staff in TB programmes require an understanding of the various competing influences on individuals undergoing treatment. Programmes need to have more flexible and people-centred approaches to service provision in order to achieve adherence, and thus improve treatment outcomes., Prospero Registration Number: CRD42020171409., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
44. Active Case Finding for Tuberculosis in India: A Syntheses of Activities and Outcomes Reported by the National Tuberculosis Elimination Programme.
- Author
-
Burugina Nagaraja S, Thekkur P, Satyanarayana S, Tharyan P, Sagili KD, Tonsing J, Rao R, and Sachdeva KS
- Abstract
India launched a national community-based active TB case finding (ACF) campaign in 2017 as part of the strategic plan of the National Tuberculosis Elimination Programme (NTEP). This review evaluated the outcomes for the components of the ACF campaign against the NTEP's minimum indicators and elicited the challenges faced in implementation. We supplemented data from completed pretested data proformas returned by ACF programme managers from nine states and two union territories (for 2017-2019) and five implementing partner agencies (2013-2020), with summary national data on the state-wise ACF outcomes for 2018-2020 published in annual reports by the NTEP. The data revealed variations in the strategies used to map and screen vulnerable populations and the diagnostic algorithms used across the states and union territories. National data were unavailable to assess whether the NTEP indicators for the minimum proportions identified with presumptive TB among those screened (5%), those with presumptive TB undergoing diagnostic tests (>95%), the minimum sputum smear positivity rate (2% to 3%), those with negative sputum smears tested with chest X-rays or CBNAAT (>95%) and those diagnosed through ACF initiated on anti-TB treatment (>95%) were fulfilled. Only 30% (10/33) of the states in 2018, 23% (7/31) in 2019 and 21% (7/34) in 2020 met the NTEP expectation that 5% of those tested through ACF would be diagnosed with TB (all forms). The number needed to screen to diagnose one person with TB (NNS) was not included among the NTEP's programme indicators. This rough indicator of the efficiency of ACF varied considerably across the states and union territories. The median NNS in 2018 was 2080 (interquartile range or IQR 517-4068). In 2019, the NNS was 2468 (IQR 1050-7924), and in 2020, the NNS was 906 (IQR 108-6550). The data consistently revealed that the states that tested a greater proportion of those screened during ACF and used chest X-rays or CBNAAT (or both) to diagnose TB had a higher diagnostic yield with a lower NNS. Many implementation challenges, related to health systems, healthcare provision and difficulties experienced by patients, were elicited. We suggest a series of strategic interventions addressing the implementation challenges and the six gaps identified in ACF outcomes and the expected indicators that could potentially improve the efficacy and effectiveness of community-based ACF in India.
- Published
- 2021
- Full Text
- View/download PDF
45. Accelerating progress towards ending tuberculosis in India.
- Author
-
Sachdeva KS
- Subjects
- Humans, India epidemiology, Tuberculosis epidemiology, Tuberculosis prevention & control
- Abstract
Competing Interests: None
- Published
- 2020
- Full Text
- View/download PDF
46. Use of Computer-Assisted Personal Interviewing and Information Management System in a Survey among HIV High-Risk Groups in India: Strengths, Weaknesses, Opportunities, and Threats Analysis.
- Author
-
Brahme R, Godbole S, Gangakhedkar R, Sachdeva KS, Verma V, and Risbud A
- Abstract
Objectives: In India, integrated biological and behavioral surveillance was carried out in 2014-2015 among high-risk key population as a part of second-generation HIV surveillance system. Computer-assisted personal interviewing and integrated information management system were used for the first time in this large national field based survey. We evaluated the strengths and weaknesses of technology use in this survey., Methods: Mixed methods comprising of the key informant's interviews and structured data collected from field interviewers were used to do the strengths, weaknesses, opportunities, and threats analysis with defined attributes., Results: Despite the challenges, the technology use in this survey was a huge success with respect to data coverage, response rates, real-time data, and acceptance by respondents. However, such techniques require more focus on the competency of human resource, training, and concurrent evaluation systems to get better data quality, time adherence, and effective use of technology., Conclusion: The recommendations resulted from this analysis will help for strategic management while designing such systems in field-based community surveys., Competing Interests: There are no conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
47. Certification of TB culture and drug susceptibility testing laboratories through the Revised National Tuberculosis Control Programme (RNTCP).
- Author
-
Sachdeva KS, Nagaraja SB, Kumar A, Kumar P, and Ramachandran R
- Subjects
- Communicable Disease Control legislation & jurisprudence, Humans, India, Quality Assurance, Health Care legislation & jurisprudence, Quality Assurance, Health Care standards, Secondary Prevention, Tuberculosis, Multidrug-Resistant microbiology, Tuberculosis, Multidrug-Resistant prevention & control, Accreditation legislation & jurisprudence, Accreditation standards, Antitubercular Agents therapeutic use, Bacteriological Techniques standards, Certification legislation & jurisprudence, Certification standards, Developing Countries, Laboratories legislation & jurisprudence, Laboratories standards, Microbial Sensitivity Tests standards, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
The RNTCP is implementing the Programmatic Management of Drug Resistant Tuberculosis (PMDT) for detecting and treating drug resistant tuberculosis (DR-TB). Diagnostic services for DR-TB is provided through a network of RNTCP certified Culture and Drug Susceptibility Testing (C&DST) laboratories.This paper describes about the process involved in certification of C&DST laboratories for different technologies used in RNTCP.
- Published
- 2012
48. Addressing poverty through disease control programmes: examples from Tuberculosis control in India.
- Author
-
Kamineni VV, Wilson N, Das A, Satyanarayana S, Chadha S, Sachdeva KS, and Chauhan LS
- Subjects
- Administrative Personnel, Catchment Area, Health economics, Community Health Planning, Community-Based Participatory Research, Cost of Illness, Cost-Benefit Analysis, Directly Observed Therapy economics, Directly Observed Therapy statistics & numerical data, Directly Observed Therapy trends, Health Promotion economics, Humans, India, Infection Control economics, Knowledge Management, Models, Organizational, Mortality trends, Outcome Assessment, Health Care economics, Outcome Assessment, Health Care methods, Quality Indicators, Health Care, Rural Population, Tuberculosis economics, Community-Institutional Relations, Health Promotion methods, Infection Control methods, Poverty statistics & numerical data, Tuberculosis prevention & control
- Abstract
Introduction: Tuberculosis remains a major public health problem in India with the country accounting for one-fifth or 21% of all tuberculosis cases reported globally. The purpose of the study was to obtain an understanding on pro-poor initiatives within the framework of tuberculosis control programme in India and to identify mechanisms to improve the uptake and access to TB services among the poor., Methodology: A national level workshop was held with participation from all relevant stakeholder groups. This study conducted during the stakeholder workshop adopted participatory research methods. The data was elicited through consultative and collegiate processes. The research study also factored information from primary and secondary sources that included literature review examining poverty headcount ratios and below poverty line population in the country; and quasi-profiling assessments to identify poor, backward and tribal districts as defined by the TB programme in India., Results: Results revealed that current pro-poor initiatives in TB control included collaboration with private providers and engaging community to improve access among the poor to TB diagnostic and treatment services. The participants identified gaps in existing pro-poor strategies that related to implementation of advocacy, communication and social mobilisation; decentralisation of DOT; and incentives for the poor through the available schemes for public-private partnerships and provided key recommendations for action. Synergies between TB control programme and centrally sponsored social welfare schemes and state specific social welfare programmes aimed at benefitting the poor were unclear., Conclusion: Further in-depth analysis and systems/policy/operations research exploring pro-poor initiatives, in particular examining service delivery synergies between existing poverty alleviation schemes and TB control programme is essential. The understanding, reflection and knowledge of the key stakeholders during this participatory workshop provides recommendations for action, further planning and research on pro-poor TB centric interventions in the country.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.